Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Netupitant/Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugate Therapy in Breast Cancer: A Randomized, Multicenter, Exploratory Phase II Study
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Jian Zhang, MD, PhD
- Telefoonnummer: 85000 +8664175590
- E-mail: syner2000@163.com
Studie Contact Back-up
- Naam: Yanchun Meng, MD
- Telefoonnummer: 63028 +8664175590
- E-mail: ycmclinicaltrials@126.com
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Age ≥ 18 years. Histologically or cytologically confirmed breast cancer. Planned to initially receive one of the following antibody-drug conjugate (ADC) agents: trastuzumab deruxtecan (T-DXd), trastuzumab rezetecan (SHR-A1811), or datopotamab deruxtecan (Dato-DXd).
Planned to use netupitant/palonosetron capsules (NEPA) prophylactically as an antiemetic prior to ADC therapy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Expected survival ≥ 3 months.
Adequate organ function, defined as:
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases); Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min. Able to understand and voluntarily sign written informed consent. Able and willing to use an electronic patient-reported outcome (ePRO) device to complete daily diary records.
Exclusion Criteria:
- Currently participating in another clinical trial that may affect the antiemetic evaluation or drug exposure of this study.
Nausea (Visual Analog Scale [VAS] ≥ 5 mm) or vomiting within 24 hours prior to enrollment.
Use of any antiemetic medication within 2 weeks prior to enrollment, including 5-HT3 receptor antagonists, NK1 receptor antagonists, glucocorticoids, metoclopramide, olanzapine, etc.
Use of benzodiazepines, opioids, or opioid-like medications within 1 week prior to enrollment or planned use during the study period (especially the Day 1-21 observation window), except single doses of midazolam, temazepam, or triazolam.
Known allergy to netupitant, palonosetron, or excipients of the NEPA capsule. Symptomatic brain metastases or leptomeningeal metastases (patients who have received treatment and been stable for ≥ 4 weeks are eligible).
Uncontrolled serious medical conditions, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), uncontrolled diabetes (HbA1c ≥ 8.0%), New York Heart Association (NYHA) functional classification ≥ III, myocardial infarction or unstable angina within 6 months, or history of clinically significant QT interval prolongation.
Psychiatric disorder or cognitive impairment that may affect the reliability of nausea/vomiting assessment or ePRO completion.
Pregnant or lactating women. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Actieve vergelijker: Standard (No Extended NEPA)
Standard antiemetic regimen consisting of netupitant/palonosetron (NEPA), dexamethasone, and olanzapine administered on Days 1-4 (Day 5: observation only). No extended NEPA dosing is given from Day 6 through Day 21. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
|
Experimenteel: Extended NEPA (3 Boosts)
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6, 11, and 16. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
|
Experimenteel: Extended NEPA (2 Boosts)
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6 and 13. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with No Nausea (VAS < 5 mm) During the 120-504 Hour Window After ADC Administration
Tijdsspanne: 120 to 504 hours (Days 6-21) after ADC administration
|
The no-nausea rate, defined as the proportion of participants with a Visual Analog Scale (VAS) nausea score < 5 mm, assessed during the 120-504 hour window (Days 6-21) following ADC (trastuzumab deruxtecan, trastuzumab rezetecan [SHR-A1811], or datopotamab deruxtecan) administration. |
120 to 504 hours (Days 6-21) after ADC administration
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with No Significant Nausea (VAS < 25 mm) During the 120-504 Hour Window
Tijdsspanne: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants with a VAS nausea score < 25 mm during the 120-504 hour window after ADC administration. |
120-504 hours (Days 6-21) after ADC administration
|
|
Percentage of Participants with No Vomiting During the 120-504 Hour Window
Tijdsspanne: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants who did not experience vomiting during the 120-504 hour window after ADC administration. |
120-504 hours (Days 6-21) after ADC administration
|
|
Complete Response (CR) Rate During the 120-504 Hour Window
Tijdsspanne: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving complete response, defined as no vomiting and no use of rescue medication, during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Complete Protection (CP) Rate During the 120-504 Hour Window
Tijdsspanne: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving complete protection (no nausea [VAS < 5 mm], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Total Control (TC) Rate During the 120-504 Hour Window
Tijdsspanne: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving total control (no nausea [VAS = 0], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Antiemetic Efficacy Across Time Windows: No Nausea, No Significant Nausea, No Vomiting, CR, CP, TC, and Rescue Medication Rates
Tijdsspanne: Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)
|
For each of four time windows (0-24 h acute, 24-120 h delayed, 0-120 h overall, and 0-504 h full course [Day 1-21]), the following binary endpoints are assessed: no nausea rate (VAS < 5 mm), no significant nausea rate (VAS < 25 mm), no vomiting rate, complete response (CR) rate, complete protection (CP) rate, total control (TC) rate, and rescue medication use rate. The 0-120 h window reflects the period in which all three arms received identical baseline antiemetic prophylaxis (Days 1-5); by design no systematic between-arm difference is expected, and this window is used to verify the comparability of baseline efficacy and the internal consistency of the study. Missing-data handling is consistent with the primary endpoint. |
Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Tekenen en symptomen, spijsvertering
- Huidziektes
- Borst ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Tekenen en symptomen
- Borstneoplasmata
- Misselijkheid
- Braken
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Farmaceutische voorbereidingen
- Doseringsvormen
- Polycyclische verbindingen
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Steroïden, gefluoreerd
- Zwangerschap
- Benzazepines
- Benzodiazepines
- Olanzapine
- Dexamethason
- Tabletten
- Netupitant, Palosentron Drug Combinatie
Andere studie-ID-nummers
Andere studie-ID-nummers
- 2610355-28
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .